Merged scale Post-merger identity as Syner-G BioPharma Group with a combined talent pool of 400+ professionals across North America, Europe, and APAC presents a larger delivery footprint and ability to take on bigger, multi-regional development programs for biopharma clients.

Lifecycle expertise Integrated offerings spanning scientific, regulatory, technical, and strategic consulting across the development lifecycle position Syner-G as a potential one-stop partner for end-to-end drug development and optimization, appealing to clients seeking streamlined vendor management.

AI and 3Di Recent launches of 3D Intelligence (3Di) and AI-augmented knowledge workflows signal a value proposition around faster decision-making and risk reduction, opening opportunities to upsell to clients pursuing digital transformation and accelerated IND-to-NDA timelines.

Strategic partnerships Active collaborations and technology partnerships (Weave for AI-augmented authoring and knowledge management) create entry points for co-delivery arrangements and cross-sell of consulting services to biopharma programs requiring regulatory intelligence, technical writing, and lifecycle management.

Recognition & growth Industry recognition as a top place to work and a track record of acquisitions and executive hires indicate a growth trajectory and stability, which can be leveraged to engage mid-market and enterprise biopharma clients seeking proven partners with scale and a strong culture.